Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012:7:83-8.
doi: 10.2147/CIA.S11829. Epub 2012 Mar 15.

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease

Eva-Maria Hametner  1 , Klaus Seppi, Werner Poewe
Affiliations
Review

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease

Eva-Maria Hametner et al. Clin Interv Aging. 2012.

Abstract

The aim of this article is to provide a short review of the most relevant pharmacological and clinical data on pramipexole extended release (ER) as well as to address the clinical utility and potential advantages of a once-daily formulation especially in the treatment of early Parkinson's disease (PD). Pramipexole is widely established as a symptomatic treatment in early as well as advanced PD. The development of an ER formulation, with stable pramipexole plasma concentration over 24 hours, now offers a bioequivalent once-daily alternative. Double-blind randomized controlled trials in early and advanced PD, have established noninferiority of pramipexole ER compared with immediate release as well as superiority of both formulations over placebo. The overnight switch from the standard to the once-daily formulation was shown to be successful in >80% of patients without requiring any dose adjustments. Potential benefits of the prolonged-release design, which have not yet been formally demonstrated in the pivotal trial program, include improved compliance and a potential for better symptomatic control, particularly in patients with early disease that can be managed with monotherapy.

Keywords: Parkinson’s disease; compliance; control; extended release; pramipexole.

PubMed Disclaimer

References

    1. Olanow C, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord. 2004;19(9):997–1005. - PubMed
    1. Holloway R, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–1053. - PubMed
    1. Gerfen C, Engber T, Mahan L, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250(4986):1429–1432. - PubMed
    1. Herrero M, Augood S, Hirsch E, et al. Effects of L-DOPA on preproen-kephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience. 1995;68(4):1189–1198. - PubMed
    1. Jolkkonen J, Jenner P, Marsden C. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Brain Res Mol Brain Res. 1995;32(2):297–307. - PubMed

Publication types